A Craigavon pharmaceutical company has launched a new global brand for its specialist medical nutrition products used in the dietary management of rare inherited metabolic diseases.

The brand, named Galsana, was announced at the SSIEM Annual Symposium in Helsinki, an international scientific conference focused on inherited metabolic disorders.

Galsana brings together a portfolio of products for conditions including Phenylketonuria, Maple Syrup Urine Disease, Tyrosinemia and Urea Cycle Disorders. It is offered through Galen Ltd and its subsidiary POA Pharma.

Galen Ltd was founded in Craigavon in 1968. The company is privately owned and has a presence in 25 markets worldwide, with more than 75 products across various therapy areas. It is a member of the Almac Group.

The launch follows Galen's acquisition of POA Pharma in 2020, which expanded its reach into the Nordic region and Northern Europe and strengthened its position in rare metabolic diseases.

Dr Dennise Broderick, managing director and president of Galen Ltd, said the company has built its reputation by understanding the needs of patients and healthcare professionals. She stated that the launch of Galsana represents the next stage for the medical nutrition business, bringing together experience and patient focus under a single global identity to support future innovation.

Dr Sarah Dolan, associate director of medical nutrition at Galen, noted that while individual rare metabolic diseases affect small patient populations, collectively they present a significant global healthcare challenge. She said the company is proud that a firm rooted in Northern Ireland can contribute to advancing care for patients worldwide while supporting the region's life sciences industry.

The company said the move is part of a long-term strategy to expand its international presence, strengthen its innovation pipeline and create opportunities for partnerships and long-term investment in Northern Ireland's life sciences sector.